Memphasys secures €526,500 Nordic deal, expanding Felix™ to nine European countries
Memphasys Limited (ASX: MEM) has entered an exclusive commercialisation agreement with NOVIVITAE ApS, appointing the Denmark-based distributor as its exclusive commercialisation partner across Denmark, Sweden, Norway, Finland and Iceland.
The agreement carries a €526,500 minimum contracted value across three Agreement Years, following a three-month evaluation period, with an immediate initial quarter order valued at €20,625 plus three Felix™ units to be supplied and invoiced in the September quarter.
The deal expands Memphasys’ European commercial footprint to nine countries, adding the five Nordic states to Italy, the United Kingdom, Türkiye and Poland. For investors, the agreement builds a contracted, recurring-revenue base and further validates the reproductive biotechnology company’s distribution-led European strategy.
When big ASX news breaks, our subscribers know first
Agreement structure and commitments
The transaction is designed around a structured pathway rather than a single one-off sale, with the following core mechanics:
-
Commences immediately, with an initial order of €20,625 to be supplied and invoiced in the September quarter.
-
A three-month evaluation period, during which commercial planning and market-development activities begin immediately.
-
A three-year commercial term with minimum contracted purchases of €526,500.
-
NOVIVITAE appointed exclusive commercialisation partner across the Nordic territory, subject to agreed minimum purchase and performance obligations.
-
Quarterly ordering requirements and increasing minimum purchase commitments over the term.
The structure emphasises a recurring model over a single transaction, providing a defined route toward growing recurring revenue as adoption builds across the region.
| Deal Element | Detail | Investor Impact |
|---|---|---|
| Contracted value | €526,500 minimum across three Agreement Years | Establishes a contracted revenue floor |
| Initial order | €20,625 plus three Felix™ units, September quarter | Near-term invoiced revenue |
| Term length | Three-year commercial term | Multi-year visibility |
| Exclusivity | NOVIVITAE as exclusive commercialisation partner | Single-partner focus across five markets |
| Revenue model | Increasing minimum commitments over the term | Structured pathway to recurring revenue |
Why the Nordic fertility market matters
Assisted reproductive technology (ART) refers to medical procedures used to help people conceive, most commonly in vitro fertilisation (IVF), where eggs and sperm are combined outside the body. The Nordic countries have sophisticated and established fertility-care systems and high utilisation of ART, making the region an attractive target for clinical technologies such as Felix™.
The latest comparable country-level data identified by Memphasys records approximately 55,000 ART treatment cycles across the five Nordic countries in 2020. This figure warrants an important caveat: the 2020 reporting period was affected by COVID-19 and is presented as a historical benchmark, not a current market forecast.
Each Felix™ procedure uses a single disposable cartridge, providing the potential for recurring revenue as clinics adopt the system and utilisation increases.
The Felix™ technology combines electrophoresis and size-exclusion membranes to isolate the most viable sperm cells for human assisted reproduction. It is designed to replace traditional centrifugation, a spinning process that can cause cellular stress and DNA damage, offering clinicians a faster, gentler and more standardised sperm selection process.
The clinical rationale underpinning Nordic clinic interest centres on the pivotal study data presented at FSANZ 2026, which demonstrated a statistically significant improvement in Embryo Utilisation Rate over density gradient centrifugation across 103 couples at 10 Monash IVF centres, alongside 100% clinician preference for Felix over the incumbent method.
About NOVIVITAE
NOVIVITAE is a Denmark-based IVF and laboratory-technology distributor that supplies products and services to IVF clinics and sperm and egg banks across the Nordic region. The distributor co-organised vitrification workshops at the Nordic IVF Laboratory Society’s 2024 meeting in Copenhagen.
Under the agreement, NOVIVITAE will:
-
Develop relationships with IVF clinics, fertility specialists, embryologists and key opinion leaders.
-
Conduct product demonstrations and training.
-
Support clinical adoption across the Nordic territory.
-
Provide first-line customer support.
Management commentary and outlook
Marjan Mikel, Memphasys Non-Executive Director and Chair of the Commercialisation Committee
“This is another important step in expanding the European commercial footprint for Felix™. With the Nordic states added to Italy, the UK, Turkey and Poland, we now have commercial arrangements across nine European countries. NOVIVITAE’s hands-on approach to introducing new technologies and driving clinic adoption makes it an ideal partner for Felix™. With a number of advanced commercial discussions progressing across Europe and our Director of Commercial Operations-Europe commencing in mid-September, we are well positioned to build on this momentum through further agreements and growth from our expanding partner network.”
Søren Venderby, NOVIVITAE Managing Director
“We are seeing strong early interest from IVF clinics across the Nordic region. Clinics are particularly interested in Felix™ clinical benefits and its potential to improve laboratory workflow and efficiency. We believe this provides a strong foundation for commercial adoption across the Nordic markets.”
Near-term activity during the three-month evaluation period will focus on four priorities:
-
Supply of the initial order.
-
Distributor training.
-
Market-development planning.
-
Clinic engagement and product demonstrations.
Quarterly minimum purchase commitments will commence following the evaluation period. The agreement signals continued momentum in Memphasys’ European roll-out, with management pointing to advanced commercial discussions progressing across the region. Investors should note, however, that revenue certainty extends only to the contracted minimums, with any additional volumes dependent on clinic adoption and utilisation over the term.
Investors exploring how Memphasys translates distributor-led European momentum into larger anchor contracts elsewhere in the portfolio will find our deep-dive into the Monash IVF national supply agreement useful, as it details how a decade-long clinical partnership converted into a 22-clinic contracted rollout covering roughly 21% of the Australian IVF market.
Don’t Miss the Next Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment news breaks. Click the “Free Alerts” button at StockWire X to start receiving alerts today.